http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 30 Jul 2026 09:13:22 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Investing/Morgan+Stanley+bullish+on+Galderma+on+stronger+Nemluvio+growth+outlook/26840322.html <p>Investing.com -- Morgan Stanley on Thursday upgraded Galderma Group AG to “overweight” from “equal-weight” and raised its price target to 210 Swiss francs from 160 Swiss francs, citing higher growth forecasts for the company’s Nemluvio drug and injectable aesthetics business after the Swiss dermatology company posted strong first-half 2026 results.</p> <p dir="ltr"></p> <p dir="ltr">The new price target implies 19% upside from Galderma’s July 29 closing price of 177.10 Swiss francs.</p> <p dir="ltr">Morgan Stanley said it raised its 2027-2030 forecasts by 5-6% on revenue, 2-5% on EBITDA and 9-11% on earnings per share, reflecting higher estimates for Nemluvio, a biologic drug for serious dermatology conditions, http://www.streetinsider.com/Investing/Morgan+Stanley+bullish+on+Galderma+on+stronger+Nemluvio+growth+outlook/26840322.html Thu, 30 Jul 2026 09:13:22 -0400 GALD http://www.streetinsider.com/General+News/Morgan+Stanley+bullish+on+Galderma+on+stronger+Nemluvio+growth+outlook/26840322.html <p>Investing.com -- Morgan Stanley on Thursday upgraded Galderma Group AG to “overweight” from “equal-weight” and raised its price target to 210 Swiss francs from 160 Swiss francs, citing higher growth forecasts for the company’s Nemluvio drug and injectable aesthetics business after the Swiss dermatology company posted strong first-half 2026 results.</p> <p dir="ltr"></p> <p dir="ltr">The new price target implies 19% upside from Galderma’s July 29 closing price of 177.10 Swiss francs.</p> <p dir="ltr">Morgan Stanley said it raised its 2027-2030 forecasts by 5-6% on revenue, 2-5% on EBITDA and 9-11% on earnings per share, reflecting higher estimates for Nemluvio, a biologic drug for serious dermatology conditions, http://www.streetinsider.com/General+News/Morgan+Stanley+bullish+on+Galderma+on+stronger+Nemluvio+growth+outlook/26840322.html Thu, 30 Jul 2026 09:13:22 -0400 GALD http://www.streetinsider.com/Press+Releases/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html <p> Ad hoc announcement pursuant to Art. 53 LR </p> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. </p><ul class="bwlistdisc"> <li> <b>Net sales reached 3.134 billion USD</b>, surpassing 3 billion USD for the first time in the first six months of the year and representing net sales growth of 24.6% at constant currency1. </li> <li> <b>Broad-based, double-digit growth in both International markets and the U.S. as well as in all product categories</b>, primarily driven by volume and complemented by favorable mix. </li> <li> <b>Outperforming the market in each product category</b>, with net sales http://www.streetinsider.com/Press+Releases/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html Thu, 23 Jul 2026 01:00:00 -0400 A.06822034 A.50201579 GALD O.12524441 O.20026344 O.53383194 http://www.streetinsider.com/Press+Releases/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html <p> Ad hoc announcement pursuant to Art. 53 LR </p> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. </p><ul class="bwlistdisc"> <li> <b>Net sales reached 3.134 billion USD</b>, surpassing 3 billion USD for the first time in the first six months of the year and representing net sales growth of 24.6% at constant currency1. </li> <li> <b>Broad-based, double-digit growth in both International markets and the U.S. as well as in all product categories</b>, primarily driven by volume and complemented by favorable mix. </li> <li> <b>Outperforming the market in each product category</b>, with net sales http://www.streetinsider.com/Press+Releases/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html Thu, 23 Jul 2026 01:00:00 -0400 A.06822034 A.50201579 GALD O.12524441 O.20026344 O.53383194 http://www.streetinsider.com/Press+Releases/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html <p> Ad hoc announcement pursuant to Art. 53 LR </p> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. </p><ul class="bwlistdisc"> <li> <b>Net sales reached 3.134 billion USD</b>, surpassing 3 billion USD for the first time in the first six months of the year and representing net sales growth of 24.6% at constant currency1. </li> <li> <b>Broad-based, double-digit growth in both International markets and the U.S. as well as in all product categories</b>, primarily driven by volume and complemented by favorable mix. </li> <li> <b>Outperforming the market in each product category</b>, with net sales http://www.streetinsider.com/Press+Releases/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html Thu, 23 Jul 2026 01:00:00 -0400 A.06822034 A.50201579 GALD O.12524441 O.20026344 O.53383194 http://www.streetinsider.com/Press+Releases/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html <p> Ad hoc announcement pursuant to Art. 53 LR </p> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. </p><ul class="bwlistdisc"> <li> <b>Net sales reached 3.134 billion USD</b>, surpassing 3 billion USD for the first time in the first six months of the year and representing net sales growth of 24.6% at constant currency1. </li> <li> <b>Broad-based, double-digit growth in both International markets and the U.S. as well as in all product categories</b>, primarily driven by volume and complemented by favorable mix. </li> <li> <b>Outperforming the market in each product category</b>, with net sales http://www.streetinsider.com/Press+Releases/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html Thu, 23 Jul 2026 01:00:00 -0400 A.06822034 A.50201579 GALD O.12524441 O.20026344 O.53383194 http://www.streetinsider.com/Press+Releases/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html <p> Ad hoc announcement pursuant to Art. 53 LR </p> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. </p><ul class="bwlistdisc"> <li> <b>Net sales reached 3.134 billion USD</b>, surpassing 3 billion USD for the first time in the first six months of the year and representing net sales growth of 24.6% at constant currency1. </li> <li> <b>Broad-based, double-digit growth in both International markets and the U.S. as well as in all product categories</b>, primarily driven by volume and complemented by favorable mix. </li> <li> <b>Outperforming the market in each product category</b>, with net sales http://www.streetinsider.com/Press+Releases/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html Thu, 23 Jul 2026 01:00:00 -0400 A.06822034 A.50201579 GALD O.12524441 O.20026344 O.53383194 http://www.streetinsider.com/Press+Releases/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html <p> Ad hoc announcement pursuant to Art. 53 LR </p> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. </p><ul class="bwlistdisc"> <li> <b>Net sales reached 3.134 billion USD</b>, surpassing 3 billion USD for the first time in the first six months of the year and representing net sales growth of 24.6% at constant currency1. </li> <li> <b>Broad-based, double-digit growth in both International markets and the U.S. as well as in all product categories</b>, primarily driven by volume and complemented by favorable mix. </li> <li> <b>Outperforming the market in each product category</b>, with net sales http://www.streetinsider.com/Press+Releases/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html Thu, 23 Jul 2026 01:00:00 -0400 A.06822034 A.50201579 GALD O.12524441 O.20026344 O.53383194 http://www.streetinsider.com/Business+Wire/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html <p> Ad hoc announcement pursuant to Art. 53 LR </p> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. </p><ul class="bwlistdisc"> <li> <b>Net sales reached 3.134 billion USD</b>, surpassing 3 billion USD for the first time in the first six months of the year and representing net sales growth of 24.6% at constant currency1. </li> <li> <b>Broad-based, double-digit growth in both International markets and the U.S. as well as in all product categories</b>, primarily driven by volume and complemented by favorable mix. </li> <li> <b>Outperforming the market in each product category</b>, with net sales http://www.streetinsider.com/Business+Wire/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html Thu, 23 Jul 2026 01:00:00 -0400 A.06822034 A.50201579 GALD O.12524441 O.20026344 O.53383194 http://www.streetinsider.com/Business+Wire/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html <p> Ad hoc announcement pursuant to Art. 53 LR </p> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. </p><ul class="bwlistdisc"> <li> <b>Net sales reached 3.134 billion USD</b>, surpassing 3 billion USD for the first time in the first six months of the year and representing net sales growth of 24.6% at constant currency1. </li> <li> <b>Broad-based, double-digit growth in both International markets and the U.S. as well as in all product categories</b>, primarily driven by volume and complemented by favorable mix. </li> <li> <b>Outperforming the market in each product category</b>, with net sales http://www.streetinsider.com/Business+Wire/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html Thu, 23 Jul 2026 01:00:00 -0400 A.06822034 A.50201579 GALD O.12524441 O.20026344 O.53383194 http://www.streetinsider.com/Business+Wire/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html <p> Ad hoc announcement pursuant to Art. 53 LR </p> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. </p><ul class="bwlistdisc"> <li> <b>Net sales reached 3.134 billion USD</b>, surpassing 3 billion USD for the first time in the first six months of the year and representing net sales growth of 24.6% at constant currency1. </li> <li> <b>Broad-based, double-digit growth in both International markets and the U.S. as well as in all product categories</b>, primarily driven by volume and complemented by favorable mix. </li> <li> <b>Outperforming the market in each product category</b>, with net sales http://www.streetinsider.com/Business+Wire/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html Thu, 23 Jul 2026 01:00:00 -0400 A.06822034 A.50201579 GALD O.12524441 O.20026344 O.53383194 http://www.streetinsider.com/Business+Wire/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html <p> Ad hoc announcement pursuant to Art. 53 LR </p> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. </p><ul class="bwlistdisc"> <li> <b>Net sales reached 3.134 billion USD</b>, surpassing 3 billion USD for the first time in the first six months of the year and representing net sales growth of 24.6% at constant currency1. </li> <li> <b>Broad-based, double-digit growth in both International markets and the U.S. as well as in all product categories</b>, primarily driven by volume and complemented by favorable mix. </li> <li> <b>Outperforming the market in each product category</b>, with net sales http://www.streetinsider.com/Business+Wire/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html Thu, 23 Jul 2026 01:00:00 -0400 A.06822034 A.50201579 GALD O.12524441 O.20026344 O.53383194 http://www.streetinsider.com/Business+Wire/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html <p> Ad hoc announcement pursuant to Art. 53 LR </p> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. </p><ul class="bwlistdisc"> <li> <b>Net sales reached 3.134 billion USD</b>, surpassing 3 billion USD for the first time in the first six months of the year and representing net sales growth of 24.6% at constant currency1. </li> <li> <b>Broad-based, double-digit growth in both International markets and the U.S. as well as in all product categories</b>, primarily driven by volume and complemented by favorable mix. </li> <li> <b>Outperforming the market in each product category</b>, with net sales http://www.streetinsider.com/Business+Wire/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html Thu, 23 Jul 2026 01:00:00 -0400 A.06822034 A.50201579 GALD O.12524441 O.20026344 O.53383194 http://www.streetinsider.com/Business+Wire/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html <p> Ad hoc announcement pursuant to Art. 53 LR </p> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. </p><ul class="bwlistdisc"> <li> <b>Net sales reached 3.134 billion USD</b>, surpassing 3 billion USD for the first time in the first six months of the year and representing net sales growth of 24.6% at constant currency1. </li> <li> <b>Broad-based, double-digit growth in both International markets and the U.S. as well as in all product categories</b>, primarily driven by volume and complemented by favorable mix. </li> <li> <b>Outperforming the market in each product category</b>, with net sales http://www.streetinsider.com/Business+Wire/Galderma+Reports+Record+First+Half+2026+Net+Sales+of+3.134+Billion+USD+and+24.6%25+Year-on-Year+Growth+at+Constant+Currency%2C+Raises+Net+Sales+Guidance+for+the+Full+Year/26803130.html Thu, 23 Jul 2026 01:00:00 -0400 A.06822034 A.50201579 GALD O.12524441 O.20026344 O.53383194 http://www.streetinsider.com/Press+Releases/Galderma+Launches+Alastin%C2%AE+in+Japan+and+Key+Markets+Across+Asia+Pacific%2C+Expanding+Its+Footprint+in+the+Region/26785849.html <ul class="bwlistdisc"> <li> Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan </li> <li> The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive procedures and an increased focus on skin quality, which are accelerating demand for innovative, science‑based skincare solutions such as Alastin1,2 </li> <li> These launches reflect Galderma’s ongoing growth across the JPAC region and long‑term commitment to advancing regenerative skincare </li> </ul> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative http://www.streetinsider.com/Press+Releases/Galderma+Launches+Alastin%C2%AE+in+Japan+and+Key+Markets+Across+Asia+Pacific%2C+Expanding+Its+Footprint+in+the+Region/26785849.html Mon, 20 Jul 2026 01:00:00 -0400 A.50213485 GALD O.24152459 O.53383194 http://www.streetinsider.com/Press+Releases/Galderma+Launches+Alastin%C2%AE+in+Japan+and+Key+Markets+Across+Asia+Pacific%2C+Expanding+Its+Footprint+in+the+Region/26785849.html <ul class="bwlistdisc"> <li> Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan </li> <li> The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive procedures and an increased focus on skin quality, which are accelerating demand for innovative, science‑based skincare solutions such as Alastin1,2 </li> <li> These launches reflect Galderma’s ongoing growth across the JPAC region and long‑term commitment to advancing regenerative skincare </li> </ul> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative http://www.streetinsider.com/Press+Releases/Galderma+Launches+Alastin%C2%AE+in+Japan+and+Key+Markets+Across+Asia+Pacific%2C+Expanding+Its+Footprint+in+the+Region/26785849.html Mon, 20 Jul 2026 01:00:00 -0400 A.50213485 GALD O.24152459 O.53383194 http://www.streetinsider.com/Press+Releases/Galderma+Launches+Alastin%C2%AE+in+Japan+and+Key+Markets+Across+Asia+Pacific%2C+Expanding+Its+Footprint+in+the+Region/26785849.html <ul class="bwlistdisc"> <li> Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan </li> <li> The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive procedures and an increased focus on skin quality, which are accelerating demand for innovative, science‑based skincare solutions such as Alastin1,2 </li> <li> These launches reflect Galderma’s ongoing growth across the JPAC region and long‑term commitment to advancing regenerative skincare </li> </ul> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative http://www.streetinsider.com/Press+Releases/Galderma+Launches+Alastin%C2%AE+in+Japan+and+Key+Markets+Across+Asia+Pacific%2C+Expanding+Its+Footprint+in+the+Region/26785849.html Mon, 20 Jul 2026 01:00:00 -0400 A.50213485 GALD O.24152459 O.53383194 http://www.streetinsider.com/Press+Releases/Galderma+Launches+Alastin%C2%AE+in+Japan+and+Key+Markets+Across+Asia+Pacific%2C+Expanding+Its+Footprint+in+the+Region/26785849.html <ul class="bwlistdisc"> <li> Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan </li> <li> The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive procedures and an increased focus on skin quality, which are accelerating demand for innovative, science‑based skincare solutions such as Alastin1,2 </li> <li> These launches reflect Galderma’s ongoing growth across the JPAC region and long‑term commitment to advancing regenerative skincare </li> </ul> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative http://www.streetinsider.com/Press+Releases/Galderma+Launches+Alastin%C2%AE+in+Japan+and+Key+Markets+Across+Asia+Pacific%2C+Expanding+Its+Footprint+in+the+Region/26785849.html Mon, 20 Jul 2026 01:00:00 -0400 A.50213485 GALD O.24152459 O.53383194 http://www.streetinsider.com/Business+Wire/Galderma+Launches+Alastin%C2%AE+in+Japan+and+Key+Markets+Across+Asia+Pacific%2C+Expanding+Its+Footprint+in+the+Region/26785849.html <ul class="bwlistdisc"> <li> Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan </li> <li> The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive procedures and an increased focus on skin quality, which are accelerating demand for innovative, science‑based skincare solutions such as Alastin1,2 </li> <li> These launches reflect Galderma’s ongoing growth across the JPAC region and long‑term commitment to advancing regenerative skincare </li> </ul> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative http://www.streetinsider.com/Business+Wire/Galderma+Launches+Alastin%C2%AE+in+Japan+and+Key+Markets+Across+Asia+Pacific%2C+Expanding+Its+Footprint+in+the+Region/26785849.html Mon, 20 Jul 2026 01:00:00 -0400 A.50213485 GALD O.24152459 O.53383194 http://www.streetinsider.com/Business+Wire/Galderma+Launches+Alastin%C2%AE+in+Japan+and+Key+Markets+Across+Asia+Pacific%2C+Expanding+Its+Footprint+in+the+Region/26785849.html <ul class="bwlistdisc"> <li> Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan </li> <li> The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive procedures and an increased focus on skin quality, which are accelerating demand for innovative, science‑based skincare solutions such as Alastin1,2 </li> <li> These launches reflect Galderma’s ongoing growth across the JPAC region and long‑term commitment to advancing regenerative skincare </li> </ul> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative http://www.streetinsider.com/Business+Wire/Galderma+Launches+Alastin%C2%AE+in+Japan+and+Key+Markets+Across+Asia+Pacific%2C+Expanding+Its+Footprint+in+the+Region/26785849.html Mon, 20 Jul 2026 01:00:00 -0400 A.50213485 GALD O.24152459 O.53383194 http://www.streetinsider.com/Business+Wire/Galderma+Launches+Alastin%C2%AE+in+Japan+and+Key+Markets+Across+Asia+Pacific%2C+Expanding+Its+Footprint+in+the+Region/26785849.html <ul class="bwlistdisc"> <li> Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan </li> <li> The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive procedures and an increased focus on skin quality, which are accelerating demand for innovative, science‑based skincare solutions such as Alastin1,2 </li> <li> These launches reflect Galderma’s ongoing growth across the JPAC region and long‑term commitment to advancing regenerative skincare </li> </ul> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative http://www.streetinsider.com/Business+Wire/Galderma+Launches+Alastin%C2%AE+in+Japan+and+Key+Markets+Across+Asia+Pacific%2C+Expanding+Its+Footprint+in+the+Region/26785849.html Mon, 20 Jul 2026 01:00:00 -0400 A.50213485 GALD O.24152459 O.53383194 http://www.streetinsider.com/Business+Wire/Galderma+Launches+Alastin%C2%AE+in+Japan+and+Key+Markets+Across+Asia+Pacific%2C+Expanding+Its+Footprint+in+the+Region/26785849.html <ul class="bwlistdisc"> <li> Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan </li> <li> The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive procedures and an increased focus on skin quality, which are accelerating demand for innovative, science‑based skincare solutions such as Alastin1,2 </li> <li> These launches reflect Galderma’s ongoing growth across the JPAC region and long‑term commitment to advancing regenerative skincare </li> </ul> <p> ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative http://www.streetinsider.com/Business+Wire/Galderma+Launches+Alastin%C2%AE+in+Japan+and+Key+Markets+Across+Asia+Pacific%2C+Expanding+Its+Footprint+in+the+Region/26785849.html Mon, 20 Jul 2026 01:00:00 -0400 A.50213485 GALD O.24152459 O.53383194 http://www.streetinsider.com/Press+Releases/Landmark+Global+Galderma+Survey+Shows+9+out+of+10+People+Are+Affected+by+Skin+Quality+Concerns/26737468.html <ul class="bwlistdisc"> <li> World’s most extensive skin quality profiling survey of more than 11,000 people across Europe, Asia, and the Americas finds that nine out of ten people are affected by skin quality concerns, with the most important attributes of good skin quality identified as smooth, hydrated and glowing skin1 </li> <li> Results show that skin quality has an impact on quality of life for 85% of people, with more than a third feeling self-conscious, insecure or anxious due to poor skin quality1 </li> <li> In response to clinicians’ calls for a universal assessment tool to help address these concerns, Galderma supported leading experts in the development of http://www.streetinsider.com/Press+Releases/Landmark+Global+Galderma+Survey+Shows+9+out+of+10+People+Are+Affected+by+Skin+Quality+Concerns/26737468.html Tue, 07 Jul 2026 01:00:00 -0400 GALD O.53383194 http://www.streetinsider.com/Press+Releases/Landmark+Global+Galderma+Survey+Shows+9+out+of+10+People+Are+Affected+by+Skin+Quality+Concerns/26737468.html <ul class="bwlistdisc"> <li> World’s most extensive skin quality profiling survey of more than 11,000 people across Europe, Asia, and the Americas finds that nine out of ten people are affected by skin quality concerns, with the most important attributes of good skin quality identified as smooth, hydrated and glowing skin1 </li> <li> Results show that skin quality has an impact on quality of life for 85% of people, with more than a third feeling self-conscious, insecure or anxious due to poor skin quality1 </li> <li> In response to clinicians’ calls for a universal assessment tool to help address these concerns, Galderma supported leading experts in the development of http://www.streetinsider.com/Press+Releases/Landmark+Global+Galderma+Survey+Shows+9+out+of+10+People+Are+Affected+by+Skin+Quality+Concerns/26737468.html Tue, 07 Jul 2026 01:00:00 -0400 GALD O.53383194 http://www.streetinsider.com/Business+Wire/Landmark+Global+Galderma+Survey+Shows+9+out+of+10+People+Are+Affected+by+Skin+Quality+Concerns/26737468.html <ul class="bwlistdisc"> <li> World’s most extensive skin quality profiling survey of more than 11,000 people across Europe, Asia, and the Americas finds that nine out of ten people are affected by skin quality concerns, with the most important attributes of good skin quality identified as smooth, hydrated and glowing skin1 </li> <li> Results show that skin quality has an impact on quality of life for 85% of people, with more than a third feeling self-conscious, insecure or anxious due to poor skin quality1 </li> <li> In response to clinicians’ calls for a universal assessment tool to help address these concerns, Galderma supported leading experts in the development of http://www.streetinsider.com/Business+Wire/Landmark+Global+Galderma+Survey+Shows+9+out+of+10+People+Are+Affected+by+Skin+Quality+Concerns/26737468.html Tue, 07 Jul 2026 01:00:00 -0400 GALD O.53383194